MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INKT MiNK Therapeutics, Inc.

Trading 03-20 10:23:36 EDT

9.38

-0.36

-3.70%

High9.61	Low9.38	Vol7.72K
Open9.50	D1 Closing9.74	Amplitude2.36%
Mkt Cap44.03M	Tradable Cap15.98M	Total Shares4.69M
T/O73.22K	T/O Rate0.45%	Tradable Shares1.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INKT","market":"US","secType":"STK","nameCN":"MiNK Therapeutics, Inc.","latestPrice":9.38,"timestamp":1774016497236,"preClose":9.74,"halted":0,"volume":7718,"delay":0,"changeRate":-0.03696098562628331,"floatShares":1703200,"shares":4694155,"eps":-3.021903,"marketStatus":"Trading","change":-0.36,"latestTime":"03-20 10:23:36 EDT","open":9.5,"high":9.61,"low":9.38,"amount":73222.549192,"amplitude":0.023614,"askPrice":9.56,"askSize":100,"bidPrice":9.23,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.021903,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"listingDate":1634270400000,"exchange":"NASDAQ","adjPreClose":9.74,"preHourTrading":{"tag":"盘前","latestPrice":9.39,"preClose":9.74,"latestTime":"09:29 EDT","volume":781,"amount":7435.571418,"timestamp":1774013370106,"change":-0.35,"changeRate":-0.035934,"amplitude":0.05576},"postHourTrading":{"tag":"盘后","latestPrice":9.55,"preClose":9.74,"latestTime":"18:34 EDT","volume":1447,"amount":13825.7798,"timestamp":1773959682948,"change":-0.19,"changeRate":-0.019507,"amplitude":0.019507},"volumeRatio":0.66959},"requestUrl":"/m/hq/s/INKT","defaultTab":"news","newsList":[{"id":"2620027410","title":"MiNK Therapeutics Appoints New Principal Financial and Accounting Officers","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027410","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027410?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:59","pubTimestamp":1773957589,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics ( ($INKT) ) has issued an announcement. On March 13, 2026, MiNK Therapeutics appointed Melissa Orilall, currently Vice President ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-appoints-new-principal-financial-and-accounting-officers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-appoints-new-principal-financial-and-accounting-officers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4162","BK4588","BK4585","BK4139","BK4534","INKT","LU1989772840.SGD","PFG","LU1989772923.USD","BK4566"],"gpt_icon":0},{"id":"2620271710","title":"Mink Therapeutics Inc - Appoints Melissa Orilall as Principal Financial Officer Effective March 13, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2620271710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620271710?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:23","pubTimestamp":1773955398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nFWN4070UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2620427179","title":"Mink Therapeutics names Melissa Orilall principal financial officer and Austin Charette principal accounting officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427179","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620427179?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:22","pubTimestamp":1773955325,"startTime":"0","endTime":"0","summary":"Mink Therapeutics appointed Melissa Orilall as Principal Financial Officer, effective March 13, 2026.Orilall is Vice President, Global Financial Operations at Agenus and previously worked at Whitehead Institute for Biomedical Research and in corporate banking.Austin Charette was appointed Principal Accounting Officer, effective March 13, 2026.Charette is Senior Director, Financial Reporting and Compliance at Agenus and previously worked at Deloitte & Touche.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6NqBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","AGEN","BK4139"],"gpt_icon":0},{"id":"2620485429","title":"Mink Therapeutics to Report Q4 and Full-Year 2025 Financial Results and Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2620485429","media":"Reuters","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620485429?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:31","pubTimestamp":1773747072,"startTime":"0","endTime":"0","summary":"Mink Therapeutics to Report Q4 and Full-Year 2025 Financial Results and Host Conference Call               Mink will report fourth-quarter and full-year 2025 financial results on March 31, 2026, befor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLpx8Fr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4588","BK4585","IE00BN0W2T93.GBP","SG9999014039.USD","SG9999014021.USD","BK4139","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","BK4112","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","INKT","LU0314104364.USD","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2620429746","title":"MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429746","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429746?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:30","pubTimestamp":1773747000,"startTime":"0","endTime":"0","summary":"Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potentialNEW YORK, Mar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257040/0/en/MiNK-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlight-Platform-Expansion-Across-iNKT-Cell-Therapy-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2619719201","title":"Mink Therapeutics Inc  expected to post a loss of 82 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719201","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619719201?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:40","pubTimestamp":1773405614,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc  expected to post a loss of82cents a share - Earnings Preview Mink Therapeutics Inc INKT.OQ INKT.O is expected to  show no change in quarterly revenue when it reports  results on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N40116J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2618656971","title":"MiNK Therapeutics Director Barbara Ryan Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618656971","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618656971?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:22","pubTimestamp":1773267763,"startTime":"0","endTime":"0","summary":"Barbara Ryan, a director of MiNK Therapeutics, Inc., reported the disposal of common shares in the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL4KDHsB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MiNK Therapeutics Director Barbara Ryan Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2618892538","title":"3 Penny Stocks to Watch Now, 3/11/26","url":"https://stock-news.laohu8.com/highlight/detail?id=2618892538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618892538?lang=en_us&edition=fundamental","pubTime":"2026-03-11 22:11","pubTimestamp":1773238260,"startTime":"0","endTime":"0","summary":"Agape ATP ($ATPC), Longeveron ($LGVN), and MiNK Therapeutics ($INKT) are the 3 Penny Stocks to watch on March 11, based on TipRanks’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-3-11-26?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-3-11-26?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","BK4175","ATPC","BK4139","LGVN"],"gpt_icon":0},{"id":"2618925818","title":"Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618925818","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618925818?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:24","pubTimestamp":1773235440,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics stock drops after a 30% rally as investors react to profit taking and a $1.1 million pediatric cancer therapy deal.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-Therapy-For-Cancer-Treatment-Concep.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-Therapy-For-Cancer-Treatment-Concep.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/03/51185634/why-is-mink-therapeutics-stock-trading-lower-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51185634/why-is-mink-therapeutics-stock-trading-lower-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2618942504","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942504","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942504?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:18","pubTimestamp":1773231489,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) shares were down 18% in Wednesday's premarket activity, shaving Tuesday's gain.AeroVironment (AVAV) stock was down 11%, a day after the company reported lower-than-expected fi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FANG.AU","CTAS","LU0823417653.USD","IE00B2Q91V27.USD","LU0950375773.USD","BK4137","IE00BGHQF524.EUR","IE00B3CCJ963.GBP","LU2506952170.USD","FANG","AVXX","LU0251142724.SGD","LU0742534661.SGD","BK4585","AVAV","LU0823417737.USD","BK4187","LU2506951875.HKD","BK4603","BK4588","BK4597","BK4213","UNF","LU0048573561.USD","LU2506951958.HKD","LU0251131958.USD","LU2506952097.USD","INKT","BK4139"],"gpt_icon":0},{"id":"2618963828","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2618963828","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618963828?lang=en_us&edition=fundamental","pubTime":"2026-03-11 02:29","pubTimestamp":1773167353,"startTime":"0","endTime":"0","summary":"Agape ATP  said Tuesday it signed an agreement with Citadel Investment, a Dubai-based investment and commodities trading firm, to jointly explore opportunities through its subsidiary in oil, gas, petroleum products, and petrochemical trading across global markets.Shares of Agape soared 55% as intraday trading volume catapulted to over 57.6 million from a daily average of roughly 788,000.MiNK Therapeutics  shares soared amid heavy trading after the company said it has entered into a strategic partnership with C-Further to develop a cell therapy for pediatric cancers.Shares jumped 27% as intraday trading volume climbed to more than 15.2 million from a daily average of about 11,000.Price: 3.13, Change: +1.11, Percent Change: +54.95","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INKT","BK4139","ATPC","BK4175"],"gpt_icon":0},{"id":"2618540999","title":"MiNK Therapeutics: Buy Rating Backed by Non-Dilutive PRAME iNKT Partnership and Expanded Oncology Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2618540999","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618540999?lang=en_us&edition=fundamental","pubTime":"2026-03-10 23:25","pubTimestamp":1773156322,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on MiNK Therapeutics, with a price target of $35.00. Emily Bodnar has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mink-therapeutics-buy-rating-backed-by-non-dilutive-prame-inkt-partnership-and-expanded-oncology-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mink-therapeutics-buy-rating-backed-by-non-dilutive-prame-inkt-partnership-and-expanded-oncology-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT"],"gpt_icon":0},{"id":"2618932987","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2618932987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618932987?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:24","pubTimestamp":1773141844,"startTime":"0","endTime":"0","summary":"Mink Therapeutics  shares were 69% higher pre-bell Tuesday after the company said it has entered into a strategic partnership with C-Further to develop a cell therapy for pediatric cancers.Zevra Therapeutics  stock was up 15%, a day after the company reported improved Q4 financial results.Teladoc Health  shares were 8% higher after Deutsche Bank  upgraded the company's stock to buy from hold.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZVRA","INKT","TDOC","BK4504","DB","BK4534","BK4167","BK4118","BK4566","BK4585","BK4588","BK4548","BK4567","LU1861559042.SGD","BK4552","LU1861558580.USD","BK4139","BK4007"],"gpt_icon":0},{"id":"2618939974","title":"BUZZ-AtaiBeckley rises as depression drug moves toward late‑stage trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939974","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618939974?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:21","pubTimestamp":1773138083,"startTime":"0","endTime":"0","summary":"BUZZ-AtaiBeckley rises as depression drug moves toward latestage trials** Shares of drugmaker AtaiBeckley ATAI.O rise 1.29% to $3.94 premarket ** Co says its experimental depression drug BPL003 will enter latestage testing in Q2 2026 after positive FDA feedback** Says BPL003 is aimed at treatmentresistant depression, a severe form of the condition where common therapies do not work** Adds nasalspray drug showed rapid, lasting benefit in midstage study, with effects seen in two days and lasting up to eight weeks** Two upcoming 12week trials, plus a yearlong extension, will test the drug against placebo - ATAI** Co reaffirms cash runway into early 2029 and reports progress on anxiety drug EMP01 and depression drug VLS01** ATAI rose about three-fold in 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL4N3ZY0U2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","ATAI","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2618367439","title":"Mink Therapeutics Shares Jump 70% Premarket After C‑Further Awarded up to $1.1 Mln to Advance Its Pediatric Cancer Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618367439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618367439?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:05","pubTimestamp":1773137135,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZY07M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2618366849","title":"BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618366849","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618366849?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:57","pubTimestamp":1773136678,"startTime":"0","endTime":"0","summary":"BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy** Shares of drug developer MiNK Therapeutics INKT.O rise 53.40% to $5.58 premarket** Co says it will receive up to $1.1 mln from C-Further to develop a cell therapy for childhood cancers** Therapy targets PRAME, a protein linked to hardtotreat cancers including sarcomas, acute myeloid leukemia and medulloblastoma, co says** Co says donorderived immune cells are designed to allow faster treatment without complex matching** Researchers at University of Southampton to run preclinical safety and efficacy studies, co says** Co's lead candidate, agenT797, is already being tested for other conditions - INKT** Share up ~60% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL4N3ZY0S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2618357329","title":"MiNK Therapeutics announces strategic collaboration with C-Further","url":"https://stock-news.laohu8.com/highlight/detail?id=2618357329","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618357329?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:40","pubTimestamp":1773135645,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced a strategic collaboration with C-Further, an international pediatric oncology therapeutics consortium enabled by...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-announces-strategic-collaboration-with-c-further-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-announces-strategic-collaboration-with-c-further-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2618935263","title":"BRIEF-MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618935263","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618935263?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:40","pubTimestamp":1773135625,"startTime":"0","endTime":"0","summary":"BRIEF-MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell TherapyMarch 10 (Reuters) - Mink Therapeutics Inc INKT.O:MINK THERAPEUTICS ANNOUNCES COLLABORATION WI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA9LLSVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2618935512","title":"MiNK Therapeutics inks C-Further collaboration with up to USD 1.1 million in non-dilutive funding for PRAME-targeted iNKT therapy development","url":"https://stock-news.laohu8.com/highlight/detail?id=2618935512","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618935512?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:30","pubTimestamp":1773135018,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics inks C-Further collaboration with up to USD 1.1 million in non-dilutive funding for PRAME-targeted iNKT therapy development. MiNK Therapeutics said it entered a non-exclusive collaboration with C-Further to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. Under the agreement, the program is eligible for up to about 1.1 million in non-dilutive aggregate payments to support IND-enabling development. The deal also provides for a meaningful double-digit share of downstream commercial revenues.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL8FLCmf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4585","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","BK4112","NDAQ","SG9999014013.SGD","LU2210149790.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","BK4139","SG9999014021.USD"],"gpt_icon":0},{"id":"2618503935","title":"Mink Therapeutics: Co to Receive $1.1 Mln Funding for Ind-Enabling Development of Its Prame-Tcr-Inkt Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2618503935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618503935?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:30","pubTimestamp":1773135000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA9LLSVD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0525},{"period":"1month","weight":-0.1288},{"period":"3month","weight":-0.1596},{"period":"6month","weight":-0.3545},{"period":"1year","weight":0.2298},{"period":"ytd","weight":-0.1265}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.041395},{"month":2,"riseRate":0.2,"avgChangeRate":-0.047548},{"month":3,"riseRate":0,"avgChangeRate":-0.093635},{"month":4,"riseRate":0.25,"avgChangeRate":-0.026851},{"month":5,"riseRate":0,"avgChangeRate":-0.100407},{"month":6,"riseRate":0.5,"avgChangeRate":0.033071},{"month":7,"riseRate":0.25,"avgChangeRate":0.215487},{"month":8,"riseRate":0.25,"avgChangeRate":0.146012},{"month":9,"riseRate":0,"avgChangeRate":-0.132506},{"month":10,"riseRate":0.5,"avgChangeRate":-0.021174},{"month":11,"riseRate":0.6,"avgChangeRate":-0.066406},{"month":12,"riseRate":0.4,"avgChangeRate":-0.119867}],"exchange":"NASDAQ","name":"MiNK Therapeutics, Inc.","nameEN":"MiNK Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MiNK Therapeutics, Inc.,INKT,MiNK Therapeutics, Inc.股票,MiNK Therapeutics, Inc.股票老虎,MiNK Therapeutics, Inc.股票老虎国际,MiNK Therapeutics, Inc.行情,MiNK Therapeutics, Inc.股票行情,MiNK Therapeutics, Inc.股价,MiNK Therapeutics, Inc.股市,MiNK Therapeutics, Inc.股票价格,MiNK Therapeutics, Inc.股票交易,MiNK Therapeutics, Inc.股票购买,MiNK Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}